- Home
- EXFY vs AGEN Comparison
EXFY vs AGEN Comparison
Compare EXFY & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXFY | AGEN |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 126.2M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | EXFY | AGEN |
|---|---|---|
| Price | $1.38 | $3.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.50 | ★ $14.50 |
| AVG Volume (30 Days) | 446.5K | ★ 883.1K |
| Earning Date | 02-26-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $143,907,000.00 | $106,829,000.00 |
| Revenue This Year | $4.44 | $5.19 |
| Revenue Next Year | $0.56 | $68.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.71 | N/A |
| 52 Week Low | $1.30 | $1.38 |
| 52 Week High | $4.00 | $7.34 |
Technical Indicators
Market Signals| Indicator | EXFY | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 35.33 |
| Support Level | $1.30 | $2.71 |
| Resistance Level | $1.48 | $2.96 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 52.27 | 8.33 |
Price Performance
Historical ComparisonAbout EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).